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Abstract: Direct and indirect effects of the new psychotropic paliperidone extended-release 
(paliperidone ER) tablets on negative symptom improvement in schizophrenia were investi-
gated using path analysis. A post hoc analysis of pooled data from three 6-week, double-blind, 
placebo-controlled studies of paliperidone ER in patients experiencing acute exacerbation was 
conducted. Regression analysis explored relationships between baseline/study characteristics 
and negative symptoms. Change in Positive and Negative Syndrome Scale (PANSS) negative 
factor score at endpoint was the dependent variable; explanatory variables included demographic 
and clinical characteristics. Path analysis determined direct and indirect effects of treatment 
on negative symptom change. Indirect mediators of negative symptom change in the model 
included changes in positive symptoms, anxiety/depression symptoms and movement disorders. 
Path analysis indicated that up to 33% of negative symptom improvement was a direct treat-
ment effect. Indirect effects on negative symptoms were mediated through changes in positive 
symptoms (51%) and anxiety/depression symptoms (18%), whereas changes in movement 
disorders had a 2.1% inverse effect. Path analysis indicated that paliperidone ER has a direct 
effect on negative symptoms. Negative symptom improvement also was indirectly mediated 
via changes in positive and depressive symptoms.
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Introduction
In the 1970s, schizophrenia researchers began to focus attention on deﬁ  ning and char-
acterizing schizophrenia psychopathology into distinct dimensions. Among the aims 
of classifying related symptoms into separate categories was to understand better how 
certain symptom clusters may change over time, how they may inﬂ  uence long-term 
outcomes and how antipsychotic treatment may affect these different manifestations 
of illness (Andreasen 1982; Carpenter et al 1985). Schizophrenia symptoms have 
been conceptualized most broadly as positive (eg, delusions, hallucinatory behavior, 
grandiosity) or negative (eg, blunted affect, emotional withdrawal, motor retardation) 
(Andreasen 1982; Kay et al 1987). Recent symptom clusters, derived from factor 
analysis of the Positive and Negative Syndrome Scale (PANSS), also include anxiety/
depression, disorganized thought and hostility/excitement (Marder et al 1997).
Incorporation of the concept of symptom clusters has clearly advanced the under-
standing of schizophrenia. However, negative symptoms have proved to be very 
difﬁ  cult to deﬁ  ne and study. As early as 1985, Carpenter et al (1985) recognized that 
negative symptoms may have multiple causes, and that not all negative symptoms are 
intrinsic to schizophrenia. They suggested that negative symptoms could be primary 
(core features) or secondary consequences of positive and/or mood symptoms, related 
to extrapyramidal side effects of certain antipsychotic medications or resulting from Neuropsychiatric Disease and Treatment 2008:4(5) 950
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understimulating social environments, such as those 
associated with institutionalization (Carpenter et al 1985; 
Moller 1993).
Because negative symptoms are associated with func-
tional disability and a poor prognosis, alleviation of such 
symptoms is an important goal of antipsychotic treatment 
(Davidson and McGlashan 1997; Milev et al 2005). Anti-
psychotic agents appear to have differential effects on 
negative symptoms. Indeed, a commonly cited distinction 
between conventional antipsychotics and atypical agents is 
the greater efﬁ  cacy of atypical antipsychotics for negative 
symptoms (Moller et al 1995; Tollefson and Sanger 1997; 
King 1998; Tandon 2004). However, it is difﬁ  cult to discern 
whether the potential beneﬁ  ts of atypical antipsychotics over 
conventional agents for negative symptoms are mediated 
through direct effects on primary symptoms, are indirect 
effects secondary to improvements in positive or mood symp-
toms or are due to the lower propensity of atypical agents to 
cause extrapyramidal symptoms (EPS) (Leucht et al 1999). 
Several atypical antipsychotic agents may improve negative 
symptoms both directly (direct effect) and indirectly (indi-
rect effect), as suggested by reports that used path analysis 
(Moller et al 1995; Tollefson and Sanger 1997; Tandon 
2004), which is an extension of multiple regression models 
(Pedhazur 1982).
Three double-blind, placebo-controlled, 6-week studies 
have demonstrated that an extended-release formulation of 
the psychotropic paliperidone (paliperidone extended-release 
[ER]) signiﬁ  cantly reduces negative symptoms in acutely ill 
patients with schizophrenia (Davidson et al 2007; Kane et al 
2007; Marder et al 2007). The objective of the present study 
was to apply path analysis to a pooled data set from these 
studies to assess the direct and indirect effects of paliperidone 
ER on negative symptom improvement.
Methods
Data for this post hoc analysis were pooled from 3 mul-
ticenter, double-blind, randomized, placebo-controlled, 
parallel-group, 6-week studies of paliperidone ER. Prelimi-
nary efﬁ  cacy and safety ﬁ  ndings of these studies have been 
reported elsewhere (Davidson et al 2007; Kane et al 2007; 
Marder et al 2007). All 3 studies had similar populations 
and identical study designs, with the same entry criteria, 
efﬁ  cacy variables, rating guidelines, rater training procedures 
and time points. Geographical regions/countries included 
Western Europe (France, Greece, The Netherlands, and 
Spain), Eastern Europe (Bulgaria, Croatia, Estonia, Poland, 
Russia, Slovakia, Ukraine, and Romania), North America 
(United States and Canada), Asia (Hong Kong, Malaysia, 
Republic of Korea, Singapore, and Taiwan), India, Israel, 
Mexico, and South Africa. Independent ethics committees or 
institutional review boards approved the ﬁ  nal study protocol 
before study initiation. Each subject provided written consent 
according to local requirements after the nature of the study 
had been fully described and was willing and able to complete 
self-administered questionnaires and be compliant with 
medication. The studies were conducted in accordance with 
current Good Clinical Practice guidelines and the Declaration 
of Helsinki and its subsequent revisions.
Subjects
Included subjects were male or female, 18 years of age, 
with a Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition (DSM-IV) diagnosis of schizophrenia 
for 1 year. Subjects had to have been experiencing active 
symptoms at the time of enrollment, with a PANSS total score 
of 70–120 points at screening and baseline, and to have agreed 
to voluntary hospitalization for at least 14 days. Female subjects 
of childbearing age had to have a negative pregnancy test result 
and be using an acceptable form of contraception.
Subjects were excluded if they had poor general health 
or chronic health conditions; a history of severe pre-existing 
gastrointestinal narrowing; any laboratory results not within 
the reference range (or deemed by the investigator to be 
clinically signiﬁ  cant); an Axis I diagnosis other than schizo-
phrenia; a DSM-IV diagnosis of substance dependence within 
6 months before screening or if deemed at signiﬁ  cant risk of 
suicide or violent behavior. Subjects were also excluded if 
they had allergy or hypersensitivity to phenytoin, carbam-
azepine, barbiturates, lamotrigine, risperidone, paliperidone, 
or olanzapine; previous lack of response to risperidone or a 
history of neuroleptic malignant syndrome. Other exclusions 
included treatment with any of the following: monoamine 
oxidase inhibitors (within 4 weeks before screening), other 
antidepressants (unless on a stable dose for 3 months 
before baseline), beta-blockers (for any use other than 
hypertension), depot antipsychotic (within 120 days before 
screening), paliperidone palmitate (within 10 months of 
screening), mood stabilizers (within 2 weeks before baseline), 
any experimental device or drug (within 90 days before 
screening), or electroconvulsive therapy (within 3 months 
before screening).
Treatment
Subjects included in this post hoc analysis were those 
randomly assigned to receive paliperidone ER (3, 6, 9, Neuropsychiatric Disease and Treatment 2008:4(5) 951
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12, or 15 mg) or placebo for 6 weeks once daily in the 
morning. No dose adjustment was permitted, except for 
a titration during the first week for subjects receiving 
paliperidone ER 15 mg.
Measures
In order to ensure inter-rater reliability, clinicians received 
training and qualiﬁ  cation on key efﬁ  cacy and safety variables. 
The primary efﬁ  cacy measures of interest in these studies 
were collected via the PANSS (Kay et al 1987). PANSS 
negative symptoms were described by the negative factor 
score (sum of blunted affect, emotional withdrawal, poor 
rapport, passive social withdrawal, lack of spontaneity, motor 
retardation, and active social avoidance), positive symptoms 
were described by the positive factor score (sum of delu-
sions, hallucinatory behavior, grandiosity, suspiciousness, 
stereotyped thinking, somatic concern, unusual thought con-
tent, lack of judgment, and insight) and anxiety/depression 
symptoms were described by the anxiety/depression factor 
score (sum of anxiety, guilty feelings, tension and depres-
sion) (Marder et al 1997). The PANSS was administered at 
baseline and study days 4, 8, 15, 22, 29, 36, and 43.
Other measures included the Clinical Global Impres-
sions–Severity (CGI-S) scale (Guy 1976) and the Personal 
and Social Performance Scale (PSP), a clinician-rated 
instrument that indicates an overall rating of personal and 
social functioning (Morosini et al 2000). The PSP mea-
sures 4 domains of functioning: socially useful activities, 
personal and social relationships, self-care, and disturbing 
and aggressive behaviors. Ratings of 71–100 indicate only 
mild difﬁ  culties; ratings of 31–70 indicate varying degrees 
of disability and ratings of 0–30 indicate functioning so poor 
that the patient requires intensive support or supervision 
(Morosini et al 2000). The PSP was administered at baseline 
and endpoint.
Safety and tolerability were assessed via adverse event 
(AE) reporting and evaluation of EPS. AEs that occurred 
between the ﬁ  rst and last study-related procedure were 
tabulated; these included AEs reported by subjects volun-
tarily, as well as those collected via interviewing of subjects 
in a nondirected manner. A treatment-emergent AE was 
deﬁ  ned as an AE that was either new in onset or increased 
in severity following the initiation of study treatment. Sub-
jects were monitored for the incidence of EPS-related AEs, 
which included tremor, dystonia, hyperkinesia, parkinson-
ism, and dyskinesia. Severity of EPS was evaluated using 
the Simpson-Angus Scale (SAS) (Simpson and Angus 
1970), the Abnormal Involuntary Movement Scale (AIMS) 
(Guy 1972), and the Barnes Akathisia Rating Scale (BARS) 
(Barnes 1989). The SAS rates 10 items, including gait, arm 
dropping, shoulder shaking, elbow rigidity, wrist rigidity, 
leg pendulousness, head dropping, glabella tap, tremor, and 
salivation, on a scale ranging from 0 (normal) to 4 (extreme). 
EPS assessments were performed at baseline and study 
weeks 1–6.
Analysis
The overall intent-to-treat (ITT) population was deﬁ  ned as 
all randomly assigned subjects who took at least one dose 
of paliperidone ER or placebo and had one postbaseline 
efﬁ  cacy assessment. The path analysis included patients in 
the overall ITT population who had no missing data at both 
baseline and endpoint on the PANSS negative, positive, 
and anxiety/depression factor scores and on the SAS scores 
(path ITT population).
Outcome variables were analyzed at the 6-week endpoint, 
which utilized the last-observation-carried-forward approach. 
Analysis of covariance (ANCOVA) models compared change 
scores at endpoint for each paliperidone ER group with 
placebo. The ANCOVA model included treatment, study 
and analysis center within study as factors and the baseline 
score for the analyzed variable as a covariate. No adjustments 
for multiplicity were performed. Least squares estimates and 
p values for pairwise differences between paliperidone ER and 
placebo groups were based on this model. Statistical testing 
was performed at the 0.05 level using 2-tailed tests.
Path analysis was used to separate the total effects of 
paliperidone ER treatment on negative symptoms into direct 
and indirect effects. For the analysis, change in the PANSS 
negative factor score at endpoint was the dependent vari-
able. Independent variables were chosen based on prior 
research (Moller et al 1995; Tollefson and Sanger 1997; 
Tandon 2004) and clinical judgment and included those that 
are thought to be mediators of negative symptom change: 
change in the PANSS positive and anxiety/depression factor 
scores and change in the SAS score for EPS at endpoint. 
Path coefﬁ  cients determined the direct and indirect effects 
of paliperidone on the negative factor score (Figure 1). 
Structural equation modeling was used to examine the direct 
and indirect effects of paliperidone on negative symptoms. 
The regression models were as follows:
ΔPositive = Baseline + P1 * Treatment
 Δ Negative = Baseline + P2 * Treatment + P5 * ΔPositive + 
P6 * ΔDepressive + P7 * ΔEPS
ΔDepressive = Baseline + P3 * Treatment
ΔEPS = Baseline + P4 * TreatmentNeuropsychiatric Disease and Treatment 2008:4(5) 952
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In these equations, ΔPositive is the change in PANSS 
positive factor score; ΔNegative is the change in PANSS 
negative factor score; ΔDepressive is the change in the 
anxiety/depression factor score; and ΔEPS is the change in 
the SAS score at endpoint. Baseline in each formula indicates 
the baseline score of the respective variable.
The total effect of treatment was determined by:
Total Effect of Treatment = P1 * P5 + P3 * P6 + P4 * 
P7 + P2
P1 through P7 in the above equation are the path coef-
ﬁ  cients and P2 is the direct effect of treatment. The direct 
effect of negative symptoms was deﬁ  ned as the treatment 
effect remaining after controlling for changes in positive 
symptoms, anxiety/depression symptoms and EPS. Path 
analysis assumes that a number of requirements have been 
met regarding the data as well as the theoretical model itself. 
Some important assumptions are that the data should follow 
a multivariate normal distribution; that there is absence of 
multicollinearity in the predictors; that error terms are uncor-
related and that a linear additive relationship exists between 
independent and dependent variables.
An initial multiple regression model was used to explore 
the relationship between negative symptoms and other 
selected demographic/clinical characteristics (ie, age, sex, 
race, change in PSP, duration of study drug exposure, duration 
since last psychotic episode) in the path ITT population.
Results
Approximately 15% of screened patients were not randomly 
assigned (2% due to missing data, and 98% due to screen 
failure). The overall ITT population included 1306 subjects 
and the path ITT population comprised 1274 subjects. 
Characteristics of the overall and path ITT populations 
were similar. A total of 937 patients in the path ITT 
population received paliperidone ER (3 mg, n = 120; 6 mg, 
n = 224; 9 mg, n = 243; 12 mg, n = 238; 15 mg, n = 112) 
and 337 patients received placebo. Baseline demographic 
and clinical characteristics were similar across treatment 
groups (Table 1). The majority of subjects were male 
(62%), mean age range was 36.2–39.5 years across the 
groups and most subjects (62%) were Caucasian. The 
most common diagnosis, occurring in 81% of patients, 
was paranoid schizophrenia. Mean baseline PANSS total 
score, ranging across groups from 91.6–94.4, reﬂ  ected an 
acutely ill population, as did mean scores for negative, 
positive and anxiety/depression factor scores. Mean SAS 
scores were also similar and low across treatment groups 
at baseline (Table 1).
Effect of paliperidone ER treatment 
on negative, positive and anxiety/
depression symptoms and EPS 
(path ITT population)
All doses of paliperidone ER resulted in signiﬁ  cant improve-
ments in negative symptom scores at endpoint compared with 
placebo (p  0.001). Signiﬁ  cant improvements for all doses 
of paliperidone ER were also noted for the positive factor 
and anxiety/depression factor scores (p  0.001). Changes 
in mean SAS scores at endpoint were signiﬁ  cantly different 
from placebo (p  0.001) in the ER paliperidone 9- and 
12-mg groups and in the combined paliperidone ER group 
(Table 2). Changes at endpoint in other efﬁ  cacy variables 
are provided in Table 2.
Treatment
Positive symptoms 
Direct effect 
EPS
Anxiety/depression
symptoms
Total treatment 
effect on negative 
symptoms   
P1
P3
P4
P5
P6
P7
P2
Figure 1 Path model illustrating the relationships between the direct and indirect effects of treatment from positive symptoms, anxiety/depression symptoms, and EPS symp-
toms on negative symptoms. P1 Through P7 are path coefﬁ  cients.
Abbreviation: EPS, extrapyramidal symptoms.Neuropsychiatric Disease and Treatment 2008:4(5) 953
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Path analysis (path ITT population)
Path analysis indicated that the total (direct and indirect) 
effects of paliperidone ER treatment resulted in greater 
improvement in negative symptoms than did placebo 
treatment. The total treatment effect was reﬂ  ected in a 
2.7-point greater improvement in the negative factor 
score in the combined treatment group than in the placebo 
group (Table 3). Paliperidone ER was shown to have 
both direct and indirect effects on negative symptoms 
(Figure 2). In the combined paliperidone ER group, the 
direct effect of treatment was indicated by a 0.89-unit 
greater improvement in negative symptoms compared with 
placebo (p = 0.0001); the direct effect of treatment on the 
negative symptoms factor score was estimated to be 33% 
(Table 3 and Figure 3). Among the domains studied, the 
largest effects of paliperidone treatment were mediated 
indirectly, through changes in positive symptoms (51%) 
and anxiety/depression symptoms (18%). Essentially no 
contribution was made by change in SAS scores (−2.1%; 
Table 3 and Figure 3). Each individual dose of paliperidone 
ER had a signiﬁ  cantly greater (p  0.05) direct effect than 
placebo on negative symptoms, which ranged from 21% for 
the 12-mg dose to 52% for the 3-mg dose. Although the 
total effect of treatment was generally consistent over 
doses, there was a differential effect on different symptom 
domains (Table 3).
Correlations between negative symptoms 
and demographic and clinical variables 
(path ITT population)
A multiple regression model explored the relationship 
between negative symptoms and demographic/clinical 
characteristics. A signiﬁ  cant relationship was found between 
improvement in negative symptoms at endpoint and duration 
of exposure to paliperidone ER (r = −0.175; p  0.001), as 
well as improvements in the PSP total score at endpoint 
(r = −0.521; p  0.001).
Tolerability and safety
Preliminary safety and tolerability data for each individual 
study have been presented elsewhere (Davidson et al 2007; 
Kane et al 2007; Marder et al 2007). Pooled data indicated 
that paliperidone ER was well tolerated. Common treat-
ment-emergent AEs (occurring in 10% of subjects in 
either the paliperidone ER combined group or placebo 
treatment arms) included headache (14% vs 12%) and 
insomnia (12% vs 15%; Table 4). Most of the frequently 
reported AEs showed no apparent dose relationship among 
paliperidone ER–treated subjects, with the exception of 
akathisia, which occurred more often in groups receiving 
9-, 12-, or 15-mg doses (Table 4). The discontinuation rate 
due to treatment-emergent AEs was similar with paliperidone 
ER (3 mg: 3%, n = 2; 6 mg: 6%, n = 15; 9 mg: 4%, n = 10; 
Table 1 Baseline demographic and clinical characteristics (path analysis intent-to-treat population; n = 1274)
Parameter Paliperidone ER daily dose
3 mg 
(n = 120)
6 mg 
(n = 224)
9 mg 
(n = 243)
12 mg 
(n = 238)
15 mg 
(n = 112)
Combined 
(n = 937)
Placebo 
(n = 337)
Age, mean years (±SD) 36.2 (10.9) 39.5 (10.6) 37.4 (11.2) 38.4 (11.0) 37.7 (9.9) 38.0 (10.8) 39.2 (11.0)
Male gender, n (%) 76 (63) 129 (58) 149 (61) 144 (61) 72 (64) 570 (61) 217 (64)
Age at diagnosis, mean years (±SD) 25.8 (8.3) 25.9 (8.6) 26.6 (8.5) 25.6 (9.0) 25.2 (7.8) 25.9 (8.5) 26.6 (9.7)
Race, n (%)
  Caucasian 58 (48) 148 (66) 169 (70) 156 (66) 50 (45) 581 (62) 210 (62)
  Black 25 (21) 58 (26) 21 (9) 63 (27) 26 (23) 193 (21) 73 (22)
  Asian 30 (25) 0 (0) 28 (12) 0 (0) 29 (26) 87 (9) 27 (8)
  Other 7 (6) 18 (8) 25 (10) 19 (8) 7 (6) 76 (8) 27 (8)
Type of schizophrenia, n (%)
  Paranoid 89 (74) 196 (88) 193 (79) 197 (83) 84 (75) 759 (81) 271 (80)
  Disorganized 7 (6) 3 (1) 13 (5) 9 (4) 6 (5) 38 (4) 13 (4)
 Catatonic 1  (1) 1 (1) 1 (1) 1 (1) 1 (1) 5 (1) 0 (0)
  Undifferentiated 22 (18) 18 (8) 31 (13) 26 (11) 18 (16) 115 (12) 46 (14)
  Residual 1 (1) 6 (3) 5 (2) 5 (2) 3 (3) 20 (1) 7 (2)
PANSS total score, mean (±SD) 91.6 (12.3) 93.4 (1.1) 93.6 (12.6) 94.4 (11.1) 92.4 (12.4) 93.4 (11.8) 93.9 (11.6)
Abbreviations: Paliperidone ER, paliperidone extended-release; PANSS, Positive and Negative Syndrome Scale; SD, standard deviation.Neuropsychiatric Disease and Treatment 2008:4(5) 954
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12 mg: 5%, n = 13; 15 mg: 4%, n = 4; all doses combined: 
5%, n = 45) and placebo (5%; n = 18).
The incidence of EPS-related AEs, which were 
examined in detail, was higher in paliperidone ER-treated 
subjects (all doses combined, 20%) compared with those 
receiving placebo (11%). This difference was due primar-
ily to higher rates of such EPS-related AEs as dystonia, 
hyperkinesia, parkinsonism, and dyskinesia in subjects 
who received higher paliperidone ER doses. EPS-related 
AEs occurred in 15 subjects (13%) receiving 3 mg of pali-
peridone ER; 24 (11%) subjects receiving 6 mg; 60 (25%) 
subjects receiving 9 mg; 62 (26%) subjects receiving 12 mg 
and 27 (24%) subjects receiving 15 mg. A total of 38 (11%) 
subjects receiving placebo had EPS-related AEs. Regardless 
of treatment, the percentages of subjects reporting the onset 
of any EPS-related AE tended to decrease over time. The 
median severity score for speciﬁ  c types of EPS was rated 
as 0 on the SAS (parkinsonism), AIMS (dyskinesia), and 
BARS (akathisia) scales for all patients receiving placebo 
or paliperidone ER at baseline and remained unchanged at 
endpoint.
Discussion
This exploratory analysis was performed to generate 
a hypothesis regarding a direct impact of paliperidone 
ER on negative symptoms. Paliperidone ER treatment, 
Table 2 Change at endpoint in path analysis variables and other clinical measures (path analysis ITT population; n = 1274)
Parameter Paliperidone ER daily dose
3 mg 
(n = 120)
6 mg 
(n = 224)
9 mg 
(n = 243)
12 mg 
(n = 238)
15 mg 
(n = 112)
Combined 
(n = 937)
Placebo 
(n = 337)
Path analysis variables
PANSS negative factor
  Baseline, mean (±SD) 22.3 (5.7) 23.2 (5.4) 23.2 (5.1) 23.6 (5.4) 23.0 (5.6) 23.2 (5.4) 23.1 (5.2)
 Endpoint  (±SD) 18.5 (6.0) 18.8 (6.1) 19.6 (6.1) 19.1 (6.0) 18.8 (6.4) 19.0 (6.1) 21.6 (6.9)
  LS mean change (±SE)a −4.2 (0.6)b −4.0 (0.4)b −3.8 (0.4)b −4.1 (0.4)b −4.4 (0.6)b −4.0 (0.2)b −1.4 (0.3)
PANSS positive factor
 Baseline  (±SD) 27.6 (4.8) 27.9 (4.9) 27.8 (5.2) 27.6 (4.8) 27.6 (5.1) 27.7 (4.9) 27.8 (4.5)
 Endpoint  (±SD) 22.5 (7.3) 21.8 (7.0) 21.7 (7.7) 20.4 (6.6) 20.8 (6.4) 21.4 (7.1) 25.4 (7.6)
  LS mean change (±SE)a −4.8 (0.7)b −5.5 (0.5)b −5.6 (0.4)b −6.9 (0.5)b −7.0 (0.7)b −6.0 (0.2)b −2.2 (0.4)
PANSS anxiety/depression factor
 Baseline  (±SD) 10.9 (3.6) 11.5 (2.9) 11.2 (3.0) 11.8 (3.3) 11.0 (3.2) 11.4 (3.2) 11.8 (3.3)
 Endpoint  (±SD) 9.1 (4.0) 9.4 (3.5) 8.9 (3.5) 9.1 (3.6) 8.5 (3.6) 9.0 (3.6) 10.9 (4.3)
  LS mean change (±SE)a −2.0 (0.4)b −2.0 (0.2)b −2.2 (0.2)b −2.5 (0.2)b −2.8 (0.4)b −2.3 (0.1)b −0.8 (0.2)
SAS scale
  Baseline 0.20 (0.34) 0.10 (0.18) 0.11 (0.21) 0.10 (0.23) 0.17 (0.33) 0.12 (0.25) 0.14 (0.27)
  Endpoint 0.13 (0.29) 0.06 (0.13) 0.15 (0.28) 0.13 (0.25) 0.15 (0.29) 0.12 (0.25) 0.09 (0.24)
  LS mean change (±SE)a −0.05 (0.02) −0.05 (0.01) 0.03 (0.01)b 0.02 (0.01)b 0.00 (0.02) −0.01 (0.01)c −0.04 (0.01)
Other variables
CGI-S
 Baseline  (±SD) 4.7 (0.7) 4.7 (0.7) 4.7 (0.7) 4.8 (0.7) 4.7 (0.7) 4.7 (0.7) 4.7 (0.7)
 Endpoint  (±SD) 3.9 (1.1) 3.8 (1.1) 3.9 (1.1) 3.7 (1.1) 3.6 (1.0) 3.8 (1.1) 4.4 (1.2)
  LS mean change (±SE)a −0.7 (0.1)b −0.8 (0.1)b −0.8 (0.1)b −1.0 (0.1)b −1.1 (0.1)b −0.9 (0.0)b −0.3 (0.1)
PSP total score
 Baseline  (±SD) 48.3 (14.0) 46.8 (13.7) 48.9 (15.2) 46.0 (13.4) 47.5 (14.2) 47.4 (14.1) 47.6 (13.9)
 Endpoint  (±SD) 56.9 (17.3) 56.0 (16.2) 56.8 (16.6) 55.4 (15.4) 59.9 (14.8) 56.7 (16.1) 48.6 (17.1)
  LS mean change (±SE)a 8.0 (1.5)b 8.4 (1.0)b 7.6 (1.0)b 8.2 (1.0)b 11.8 (1.6)b 8.5 (0.5)b 0.4 (0.8)
aANCOVA model with treatment, study and analysis center within study as factors; the baseline score for the analyzed variable as a covariate.
bp  0.001 vs placebo; cp  0.005 vs placebo.
Note: Adjustments for multiple comparisons were not performed.
Abbreviations: CGI-S, Clinical Global Impression-Severity; ER, extended-release; ITT, intent-to-treat; LS, least squares; PANSS, Positive and Negative Syndrome Scale; PSP, 
Personal and Social Performance Scale; SAS, Simpson-Angus Rating Scale; SE, standard error.Neuropsychiatric Disease and Treatment 2008:4(5) 955
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compared with placebo, was associated with a signiﬁ  cant 
improvement in negative symptoms, representing a 22% 
reduction from baseline. In the context of this acutely ill 
population, in whom a reduction in negative symptoms may 
be particularly difﬁ  cult to detect, this degree of improvement 
may be meaningful. A clinically meaningful response in nega-
tive symptoms has not yet been determined (Kirkpatrick et al 
2006). Although improvement in negative symptoms was 
indirectly mediated through changes in positive and anxiety/
depression symptoms, this analysis supports the hypothesis 
that paliperidone ER may also have a direct effect on the 
negative symptoms of schizophrenia in an acutely ill patient 
population. Changes in EPS had little effect on changes in 
negative symptoms.
These results are generally consistent with results of 
previous path analyses that examined direct and indirect 
effects of risperidone vs haloperidol (Moller et al 1995), 
olanzapine vs haloperidol and placebo (Tollefson and Sanger 
1997) and quetiapine vs placebo (Tandon 2004). All three 
of these studies demonstrated a direct effect of treatment 
on negative symptoms, although the mediators of indirect 
effects differed. Different populations, study designs, and 
assessments (particularly the different symptom rating 
scales and clusters used in the various path analytic models) 
Table 3 Estimated path coefﬁ  cients and corresponding percentage effect on PANSS Negative Symptom Factor Score (path analysis ITT 
population; n = 1274)
Paliperidone ER vs placebo
3 mg 
(n = 120)
6 mg 
(n = 224)
9 mg 
(n = 243)
12 mg 
(n = 238)
15 mg 
(n = 112)
Combined 
(n = 937)
Direct effect (%) −1.405 (52) −1.173 (41) −0.760 (33) −0.612 (21) −0.805 (28) −0.891 (33)
Indirect, change in positive symptoms (%) −0.934 (35) −1.259 (44) −1.107 (49) −1.870 (64) −1.620 (56) −1.387 (51)
Indirect, change in anxiety/depression 
symptoms (%)
−0.351 (13) −0.446 (15) −0.527 (23) −0.527 (18) −0.500 (17) −0.504 (18)
Indirect, change in EPS (%) −0.004 (0.14) −0.003 (0.11) 0.115 (−5) 0.085 (−2.9) 0.046 (−1.6) 0.058 (−2.1)
Total effect of treatment on change in 
negative symptoms
−2.694 −2.881 −2.279 −2.923 −2.888 −2.723
r2 estimate 0.350 0.388 0.333 0.422 0.345 0.420
GFI 0.8897 0.8850 0.8746 0.8849 0.8843 0.8895
Notes:   The r2 estimate represents the proportion of the total variation of changes in negative symptoms that is explained by the treatment effect.   The GFI is analogous to a 
squared multiple correlation; it indicates the proportion of the observed covariance explained by the model covariance. The GFI varies from 0 to 1, with 1 being a perfect ﬁ  t.
Abbreviations: EPS, extrapyramidal symptoms; ER, extended-release; GFI, Goodness of Fit Index; PANSS, Positive and Negative Syndrome Scale; ITT, intent-to-treat.
Treatment
Positive symptoms
Direct effect 
EPS
Anxiety/ depression 
symptoms
Total treatment effect 
on negative  
symptoms
(−3.95)
(−1.58)
(0.03)
(0.35)
(0.32)
(1.71)
−0.89;  p = 0.0001
−1.39
−0.50
0.06
Figure 2 Estimated path coefﬁ  cients for the comparisons of effects of all paliperidone ER doses combined vs placebo.
The numbers in parentheses are the coefﬁ  cients of the intermediate paths; the coefﬁ  cient of the indirect path can be obtained by multiplying the coefﬁ  cients of the intermediate 
paths. Sample interpretation, for positive symptoms: the ﬁ  rst intermediate path shows that paliperidone ER treatment (all doses combined) was associated with a P1: −3.95-unit 
greater change in positive symptoms than placebo, after controlling for the baseline score; the second intermediate path shows that there was a P5: 0.35-unit effect of positive 
symptoms on negative symptoms, after controlling for the other symptoms. The product of the intermediate path coefﬁ  cients ([−3.95]*[0.35] = −1.39) shows that paliperidone 
ER treatment (all doses combined) was associated with a 1.39-unit greater improvement in negative symptoms via positive symptom improvement vs placebo.
Abbreviations: EPS, extrapyramidal symptoms; ER, extended-release.Neuropsychiatric Disease and Treatment 2008:4(5) 956
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(Tollefson and Sanger 1997; Tandon 2004) may account for 
any disparities in study ﬁ  ndings.
Duration of exposure to paliperidone ER and improve-
ment in functioning were significantly correlated with 
improvement in negative symptoms. Our data for duration 
of drug exposure are consistent with previous research high-
lighting that continued antipsychotic treatment is associated 
with optimal outcomes in multiple symptom domains and 
decreases in the likelihood of relapse and rehospitalization 
(Ayuso-Gutierrez and del Rio Vega 1997; Docherty et al 
2002; Valenstein et al 2002; Weiden et al 2004; Gharabawi 
et al 2007).
The ﬁ  nding that functioning and negative symptoms are 
linked is also consistent with previous work (Milev et al 
2005) and emphasizes the damaging effects that negative 
symptoms have on the ability of patients with schizophrenia 
to participate fully in society.
Pooled safety data indicated that paliperidone ER was 
generally well tolerated. Discontinuations related to treat-
ment-emergent AEs were similarly low for patients receiving 
paliperidone ER or placebo. Although the incidence of 
EPS-related AEs was higher in paliperidone ER-treated 
patients, primarily those receiving higher doses, the severity 
of EPS was very low throughout the study.
Several study limitations must be noted. Path analysis 
requires the usual assumptions of regression with a linear 
relationship among variables, no or minimal multicollinearity 
in the predictors, multivariate normal data and absence of 
measurement error. The goodness-of-ﬁ  t index ranged from 
0.88 to 0.89, less than the acceptable ﬁ  t range of 0.9. 
Univariate and multivariate normality test results indicated 
that there are some moderate violations of this assumption; 
however, for this study, the sample size was large enough 
to support the asymptotic multivariate normal distribution 
for obtaining robust estimates. A Pearson Correlation Matrix 
was calculated to test the multicollinearity in the predictors. 
All the correlations were 0.2 with p values 0.05. Path 
analysis is particularly sensitive to model speciﬁ  cation; 
failure to include relevant causal variables or the inclusion 
of extraneous variables can substantially affect results. In 
addition, path analysis can only consider the secondary 
effects of factors included in the model. Although the factors 
P
e
r
c
e
n
t
a
g
e
 
e
f
f
e
c
t
 
r
e
l
a
t
i
v
e
 
t
o
 
t
o
t
a
l
 
e
f
f
e
c
t
Direct
effect
Positive factor 
score change
Anxiety/
depression factor 
score change
SAS score
change
Indirect effects
33
51
18
–2.1
–20
0
20
40
60
80
100
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chosen for use in the present analysis are considered the 
major contributors to negative symptoms in schizophrenia, 
the possibility that other unidentiﬁ  ed factors contributed to 
the results cannot be completely eliminated. The r2 estimates 
ranged from 0.33 to 0.44. Furthermore, the measure for 
movement disorders used in our path model was the SAS, 
which rates symptoms of parkinsonism and may not be 
a comprehensive measure of the various types of motor 
disorders. However, parkinsonism, rather than dyskinesia 
or akathisia, is the type of movement disorder most likely to 
confound the assessment of negative symptoms (Prosser et al 
1987). Improvements in negative symptoms in paliperidone 
ER vs placebo groups were observed in the paliperidone-
treated group, which reported a 20% rate of EPS-related AEs 
(EPS-related AEs were reported by 11% of placebo-treated 
subjects). Nonetheless, future analysis should further explore 
the effect of different types of movement disorders on nega-
tive symptoms. It should be noted that this was a post hoc 
analysis of phase 3 paliperidone studies (Davidson et al 2007; 
Kane et al 2007; Marder et al 2007); these studies were not 
designed to assess direct or indirect treatment effects on 
negative symptoms. Further, to assess better the impact of 
treatment on negative symptoms, prospective studies with a 
longer duration and patient populations with minimal posi-
tive symptoms and persistent negative symptoms should be 
conducted, as recommended by the National Institute of 
Mental Health Measurement and Treatment Research to 
Improve Cognition in Schizophrenia consensus statement on 
negative symptoms (Kirkpatrick et al 2006). Finally, there 
was no evaluation of the reliability of ratings after initial 
training, a limitation typical to this type of study.
In summary, within the limitations of the path analysis 
method used here, these data suggest that paliperidone ER 
improves the negative symptoms of schizophrenia through 
a direct effect as well as an indirect effect on positive and 
mood symptoms. Given the substantial impact that negative 
symptoms have on patient functioning, it will be of great 
interest to explore how paliperidone ER may affect negative 
symptoms and outcomes during long-term treatment in a 
prospectively deﬁ  ned study.
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